AbCellera Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABCL Nasdaq 8731 https://www.abcellera.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbCellera Biologics Inc

AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 - Feb 1st, 2023 9:05 pm
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 - Jan 24th, 2023 9:05 pm
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock? - Jan 24th, 2023 1:48 pm
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating - Jan 23rd, 2023 4:00 pm
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Jan 20th, 2023 12:00 am
Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist? - Jan 19th, 2023 4:59 pm
Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength? - Jan 12th, 2023 9:55 am
AbCellera Biologics Inc.'s (NASDAQ:ABCL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Jan 5th, 2023 2:09 pm
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 - Jan 4th, 2023 9:05 pm
Trade Alert: The CEO, President & Chairperson Of AbCellera Biologics Inc. (NASDAQ:ABCL), Carl Hansen, Has Just Spent US$859k Buying A Few More Shares - Dec 22nd, 2022 10:08 am
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie - Dec 16th, 2022 3:02 pm
AbCellera and AbbVie Partner to Advance New Antibody Therapies - Dec 15th, 2022 12:00 pm
Is There An Opportunity With AbCellera Biologics Inc.'s (NASDAQ:ABCL) 43% Undervaluation? - Dec 14th, 2022 1:18 pm
Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options - Dec 12th, 2022 1:54 pm
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases - Dec 1st, 2022 12:00 pm
IBD Stock Of The Day AbCellera Is Pulling Back — Why Investors Should Be Paying Attention - Nov 29th, 2022 9:10 pm
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 - Nov 10th, 2022 1:05 pm
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript - Nov 9th, 2022 4:00 am
AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates - Nov 8th, 2022 11:35 pm
AbCellera Reports Q3 2022 Business Results - Nov 8th, 2022 9:05 pm